Actinium downgraded despite positive data at William Blair

William Blair analyst Andy Hsieh downgraded Actinium Pharmaceuticals to Market Perform from Outperform without a price target. Results from the Phase III SIERRA trial, which examines the safety and efficacy of Iomab-B as a targeted conditioning regimen for hematopoietic stem cell transplant in relapsed or refractory acute myeloid leukemia, represent a "significant milestone" for the company, the analyst tells investors in a research note. Despite the positive data, Blair downgraded Actinium citing the uncertainties related to Iomab-B’s market expansion potential in light of "potentially practice-changing data" presented at the American Society of Hematology last year, along with difficulties in commercializing a complex modality targeting a niche disease segment. And beyond Iomab-B, Actinium does not have significant data flow from Actimab-A until 2024 or 2025, the analyst tells investors in a research note.